DDInter1042 DDInter1429
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Perflutren {u} (Compound) resembles {v} (Compound) Sevoflurane
Perflutren {u} (Compound) is included by {v} (Pharmacologic Class) Ultrasound Contrast Activity
Perflutren {u} (Compound) causes {v} (Side Effect) Haemoglobin
Perflutren {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Perflutren (Compound) resembles Sevoflurane (Compound)
Perflutren (Compound) is included by Ultrasound Contrast Activity (Pharmacologic Class)
Perflutren (Compound) causes Haemoglobin (Side Effect)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Perflutren may lead to a major life threatening interaction when taken with Cabozantinib
Perflutren may lead to a major life threatening interaction when taken with Anagrelide